Use of ceftaroline in complicated methicillin-resistant staphylococcus aureus bacteremia

Hadeel Zainah; Jose A. Vazquez

doi:10.1097/IPC.0b013e3182602205

Use of ceftaroline in complicated methicillin-resistant staphylococcus aureus bacteremia

Hadeel Zainah, Jose A. Vazquez

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Ceftaroline is a novel broad-spectrum cephalosporin approved in October 2010 by the Food and Drug Administration for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by different organisms, including methicillin-resistant Staphylococcus aureus. We report 2 cases where ceftaroline was used effectively to treat complicated methicillin-resistant S aureus bacteremia.

Original language	English (US)
Pages (from-to)	58-60
Number of pages	3
Journal	Infectious Diseases in Clinical Practice
Volume	21
Issue number	1
DOIs	https://doi.org/10.1097/IPC.0b013e3182602205
State	Published - Jan 1 2013
Externally published	Yes

Keywords

MRSA
bacteremia
ceftaroline

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/IPC.0b013e3182602205

Cite this

@article{99d816e82493499c9a919a96eab93496,

title = "Use of ceftaroline in complicated methicillin-resistant staphylococcus aureus bacteremia",

abstract = "Ceftaroline is a novel broad-spectrum cephalosporin approved in October 2010 by the Food and Drug Administration for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by different organisms, including methicillin-resistant Staphylococcus aureus. We report 2 cases where ceftaroline was used effectively to treat complicated methicillin-resistant S aureus bacteremia.",

keywords = "MRSA, bacteremia, ceftaroline",

author = "Hadeel Zainah and Vazquez, {Jose A.}",

year = "2013",

month = jan,

day = "1",

doi = "10.1097/IPC.0b013e3182602205",

language = "English (US)",

volume = "21",

pages = "58--60",

journal = "Infectious Diseases in Clinical Practice",

issn = "1056-9103",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Use of ceftaroline in complicated methicillin-resistant staphylococcus aureus bacteremia

AU - Zainah, Hadeel

AU - Vazquez, Jose A.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Ceftaroline is a novel broad-spectrum cephalosporin approved in October 2010 by the Food and Drug Administration for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by different organisms, including methicillin-resistant Staphylococcus aureus. We report 2 cases where ceftaroline was used effectively to treat complicated methicillin-resistant S aureus bacteremia.

AB - Ceftaroline is a novel broad-spectrum cephalosporin approved in October 2010 by the Food and Drug Administration for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by different organisms, including methicillin-resistant Staphylococcus aureus. We report 2 cases where ceftaroline was used effectively to treat complicated methicillin-resistant S aureus bacteremia.

KW - MRSA

KW - bacteremia

KW - ceftaroline

UR - http://www.scopus.com/inward/record.url?scp=84872062378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872062378&partnerID=8YFLogxK

U2 - 10.1097/IPC.0b013e3182602205

DO - 10.1097/IPC.0b013e3182602205

M3 - Article

AN - SCOPUS:84872062378

SN - 1056-9103

VL - 21

SP - 58

EP - 60

JO - Infectious Diseases in Clinical Practice

JF - Infectious Diseases in Clinical Practice

IS - 1

ER -

Use of ceftaroline in complicated methicillin-resistant staphylococcus aureus bacteremia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this